| About the author: |
Garashova M.A. |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The study included a retrospective analysis of the medical histories of 301 women with various tumors of the reproductive system (Average age 61.6±0.4 years). The prospective study included 306 women with benign and malignant genital tumors in the postmenopausal period (Average age 59.3±0.4 years). All patients underwent genital echography; the levels of steroid hormones and blood biochemical parameters were studied; indicators of the cancer marker CA-125 were determined. It was found that in patients with ovarian cancer, the body mass index was 28.7±0.6 kg / m2, in endometrial cancer 32.7±1.0 kg/m2, in benign ovarian neoplasms, the BMI was in the range of 27.3±2.0 kg/m2, in patients with endometrial hyperplastic processes 31.9±0.8 kg / m2. Patients with ovarian cancer and endometrial cancer had a high rate of artificial termination of pregnancy (29.2% and 46.8%, respectively). Thus, risk factors for the development of neoplastic processes of genitalia in postmenopausal period are: the increase in body mass index, presence of infertility in anamnesis, the presence of gynecological and endocrine diseases in the reproductive and perimenopausal periods, high frequency of induced abortion in anamnesis. |
| Tags |
postmenopausal period, ovarian cancer, endometrial cancer, endometrial hyperplastic processes, body mass index |
| Bibliography |
- Chernobay A. Rak yaichnikov: patogenez, diagnostika, sovremennye aspekty lecheniya. Visnyk problem biolohiyi i medytsyny. 2013; 2 (100): 33–38. [in Russian]
- Chestnova G, Kulyushina E, Abashin V, Efimenko N. Osobennosti diagnostiki giperplasticheskih processov v endometrii u zhenshhin v period dlitelnoy postmenopauzy. Klinicheskaja Meditsina. 2013; 9: 46-47. [in Russian]
- Sheshukova N, Makarov I. Otsenka funktsionalnogo statusa slizistoy obolochki tela matki u patsientok s giperplasticheskimi processami endometriya. Akush. i ginekol. 2012; 2: 72-75. [in Russian].
- Antunes A, Andrade L, Pinto G. Is the immunohistochemical expression of proliferation (Ki-67) and apoptosis (Bcl-2) markers and cyclooxigenase-2 (COX-2) related to carcinogenesis in postmenopausal endometrial polyps? Anal.Quant.Cytol.Histol., 2012; 34(5):.264–72.
- Bonadona V. Cancer risks associated with germiline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA, 2011; 35 (22) : 2304–2310.
- Brinton L, Felix A. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Biomarkers Prev. 2018; 27(9): 985-994. doi: 10.1158/1055-9965. EPI-18-0264
- Crosbie E, Roberts C, Qian W, Swart A, Kitchener H. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from eh MRC ASTEC trial. Eur.J.Cancer. 2012; 48: 853–864.
- Khatun S. Menopause and Gynecological Malignancy. J. South Asian Federation of Menopause Societies. 2013; 1(2):75-79.
- Kim M, Im Sun-Wha. Park H. The Demographic Changes of Menopausal and Geripausal Women in Korea. JBM.. 2015; 22: 23–28. http://dx.doi.org/10.11005/jbm.2015.22.1.23
- Kobayashi H, Tanase Y, Kawaguchi R, Takahama J. Factors that Differentiate between Endometriosis-associated Ovarian Cancer and Benign Ovarian Endometriosis with Mural Nodules. Magn Reson Med Sci. 2017; 3 :231-237 https://doi.org/10.2463/mrms.mp.2016–0149.
- La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur.J. Cancer.Prev. 2017; 2 (1): 55–62.
- Lee A, Ness R, Roman L, Terry K. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Am.J. Obstet.Gynecol. 2016; 127 (5): 828–836.
- Santoro N, Taylor E. Reproductive hormones and the menopause transition. Obstet.Gynecol.Clin.North Am. 2011; 38(3): 455–466.
- Sioban D.H, Margery G, Janet E. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. The Journal of The North American Menopausal Society. 2012; 19 (4) :1–9
- Smith E, Yeasky T, Wei J, Miki R, Cai K, Smedberg J. White spotting variant mouse as an experimental model for ovarian aging and menopausal biology. Menopause. 2012; 19:588–596. doi:10.1097/gme.0b013e318239cc53.
|
| Publication of the article |
«World of Medicine and Biology» №3(73), 2020 year, 037-042 pages, index UDK 618.11-006-02-036;616-006 |
| DOI |
10.26724/2079-8334-2020-3-73-37-42 |
